Ask AI
ProCE Banner Activity

Interactive Decision Support Tool: Expert Recommendations on Treatment for Relapsed/Refractory Multiple Myeloma

Tool

Use this Interactive Decision Support Tool to compare your choices of therapy for patients with relapsed/refractory multiple myeloma with those of 5 renowned experts.

Released: November 05, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an independent medical education grant from GSK.

GSK

Target Audience

This activity is intended for oncologists, hematologists, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnostic criteria, staging criteria, and risk factors
  • Develop initial treatment strategies optimized for individual patients with newly diagnosed multiple myeloma based on current guidelines, approvals, evidence, patient characteristics, and patient goals and preferences

  • Plan treatment sequences incorporating recently approved or investigational therapies for patients with relapsed/refractory multiple myeloma based on the latest evidence, expert recommendations, access, and individual patient and disease characteristics

  • Implement supportive care approaches to manage treatment-related adverse events, symptoms, and complications in patients with multiple myeloma

  • Evaluate strategies to address disparities in timely initiation of therapy, access to novel therapies and clinical trials, and supportive care in Black, older, and underserved patients with multiple myeloma

  • Assess the eligibility of patients at all stages of multiple myeloma for enrollment on clinical trials of novel therapeutic approaches with the potential to enhance clinical outcomes

Financial Disclosures

Primary Author

Jesus G. Berdeja, MD: researcher: AstraZeneca, Bristol Myers Squibb, C4 Therapeutics, Caribou, Genentech, GSK, Gracell, Ichnos, Johnson & Johnson, Juno, K36 Therapeutics, Karyopharm, Kite, Pfizer, Roche, Sanofi; consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Galapagos, Johnson & Johnson, Karyopharm, Kite, Kyowa Kirin, Pfizer, Regeneron, Roche.

Sarah A. Holstein, MD, PhD: researcher: Bristol Myers Squibb.

Carol Ann Huff, MD: consultant/advisor/speaker: Alexion, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Legend Biotechnologies, Sanofi; researcher: Johnson & Johnson, Pharmacyclics.

Shaji K. Kumar, MD: consultant: AbbVie, ArcellX, BD Biosciences, Beigene, Bristol Myers Squibb, GSK, Janssen, K36, Moderna, Pfizer, Regeneron, Roche/Genentech, Sanofi, Siemens; researcher (paid to institution): AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, Gracell Bio, GSK, Janssen, Oricell, Roche/Genentech, Sanofi, Takeda, TeloGenomics.

Sagar Lonial, MD, FACP, FASCO: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GSK, Janssen, Novartis, Pfizer, Regeneron, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; individual publicly traded stock/stock options: TG Therapeutics.